Boston Scientific Corporation $BSX Shares Sold by China Universal Asset Management Co. Ltd.

Key Points

• China Universal Asset Management trimmed its stake in Boston Scientific by 68.8% in Q4, selling 22,000 shares and leaving 10,000 shares valued at $954,000.
• Q1 results beat modestly—EPS $0.80 vs $0.79 and revenue $5.20B (up 11.6% year-over-year)—but management cut 2026 guidance (Q2 EPS 0.820–0.840; FY 3.340–3.410), and shares were trading down about 5.6%.
• Analysts have trimmed price targets and the consensus rating is a Moderate Buy with a $93.91 target, while CEO Michael Mahoney sold 160,901 shares for roughly $15.04M, underscoring mixed sentiment and notable insider activity.

China Universal Asset Management Co. Ltd. trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 68.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the medical equipment provider's stock after selling 22,000 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in Boston Scientific were worth $954,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Mowery & Schoenfeld Wealth Management LLC increased its stake in Boston Scientific by 7.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 2,501 shares of the medical equipment provider's stock worth $238,000 after purchasing an additional 181 shares during the period. N.E.W. Advisory Services LLC boosted its stake in shares of Boston Scientific by 75.0% in the fourth quarter. N.E.W. Advisory Services LLC now owns 700 shares of the medical equipment provider's stock valued at $67,000 after purchasing an additional 300 shares during the period. Diversified Enterprises LLC boosted its stake in shares of Boston Scientific by 9.7% in the fourth quarter. Diversified Enterprises LLC now owns 3,856 shares of the medical equipment provider's stock valued at $368,000 after purchasing an additional 340 shares during the period. Outfitters Financial LLC grew its holdings in shares of Boston Scientific by 0.5% in the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider's stock valued at $2,291,000 after purchasing an additional 110 shares in the last quarter. Finally, Chicago Partners Investment Group LLC grew its holdings in shares of Boston Scientific by 19.8% in the fourth quarter. Chicago Partners Investment Group LLC now owns 7,338 shares of the medical equipment provider's stock valued at $679,000 after purchasing an additional 1,214 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Down 5.6%

Shares of NYSE:BSX opened at $62.01 on Friday. Boston Scientific Corporation has a 52 week low of $59.38 and a 52 week high of $109.50. The company's 50 day moving average is $68.45 and its two-hundred day moving average is $85.78. The company has a market cap of $92.16 billion, a PE ratio of 25.95, a P/E/G ratio of 1.08 and a beta of 0.78. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analysts' expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The company's revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.34% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on BSX. Sanford C. Bernstein reiterated an "outperform" rating and set a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Jefferies Financial Group dropped their price target on shares of Boston Scientific from $110.00 to $100.00 and set a "buy" rating for the company in a research note on Wednesday. Stifel Nicolaus cut their price objective on Boston Scientific from $90.00 to $85.00 and set a "buy" rating on the stock in a research report on Tuesday. Canaccord Genuity Group reduced their price objective on Boston Scientific from $109.00 to $71.00 and set a "buy" rating on the stock in a research note on Thursday. Finally, UBS Group lowered their target price on Boston Scientific from $120.00 to $105.00 and set a "buy" rating for the company in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $93.91.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat consensus — revenue grew ~11.6% and EPS topped estimates, showing underlying demand and execution that underpinned an initial share pop after the report. Boston Scientific Corporation NYSE: BSX Q1 2026 Earnings Call Transcript
• Positive Sentiment: Unusual call-option activity — heavy call buying was reported around the earnings period, indicating some traders are positioning for a rebound or event-driven upside. Traders Purchase High Volume of Boston Scientific Call Options NYSE: BSX
• Neutral Sentiment: Analyst views are mixed and the investment story is being reset — several coverage teams trimmed fair-value estimates and split between seeing a buy opportunity versus emphasizing execution risk. This creates divergence in short‑to‑medium term expectations. How The Investment Story Is Resetting For Boston Scientific (BSX) After Recent Analyst Shifts
• Negative Sentiment: Company trimmed 2026 profit and revenue outlook — management lowered full‑year guidance (Q2 trough flagged), which directly reduced near‑term earnings visibility and is the primary driver of the pullback. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Analysts slashed price targets after Q1/guidance — multiple firms trimmed targets (Truist, Baird, Needham, others), which amplifies selling pressure and reduces near‑term analyst support. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
• Negative Sentiment: Multiple securities‑class action notices and law‑firm solicitations — several firms are soliciting lead‑plaintiff candidates tied to a July 2025–Feb 2026 class period, increasing legal risk and potential headline volatility. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Downgrades and new 52‑week low headlines — coverage noting downgrades and a 52‑week low contributes to technical selling and stops being hit. Boston Scientific NYSE: BSX Hits New 52-Week Low After Analyst Downgrade

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.